Doripenem is a carbapenem-class β-lactam antibiotic used to treat serious bacterial infections, particularly those caused by Pseudomonas aeruginosa and other Gram-negative pathogens. It has broad-spectrum activity and is structurally related to other carbapenems like meropenem and imipenem. Doripenem is administered intravenously (IV) and is primarily used in hospital settings for complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and nosocomial pneumonia.
Parent: Doripenem
Impurities in doripenem can result from manufacturing, degradation, and storage conditions, which may impact drug stability and effectiveness.
Related Substances
These are structurally related compounds formed during the synthesis process. Strict quality control measures ensure these do not exceed permissible limits.
Degradation Products
Doripenem is unstable in aqueous solutions and susceptible to hydrolysis and oxidation, leading to the formation of degradation products. Proper storage at low temperatures and protection from moisture is required to maintain its potency.
Residual Solvents
Residual solvents used during manufacturing must be monitored and controlled to comply with regulatory guidelines, ensuring patient safety.
Analytical Techniques for Monitoring Impurities
Techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (LC-MS) are used to detect and quantify impurities in doripenem formulations.
Doripenem is contraindicated in patients with a history of severe hypersensitivity (allergic) reactions to carbapenems, penicillins, or cephalosporins. It should also be used with caution in patients with renal impairment due to increased risk of toxicity.
Doripenem was voluntarily discontinued by the manufacturer due to low market demand rather than safety concerns. However, studies indicated reduced efficacy for ventilator-associated bacterial pneumonia (VABP) compared to alternative treatments, limiting its clinical use.
Doripenem and meropenem have similar antibacterial spectra, but meropenem is more commonly preferred due to greater clinical experience, better efficacy data, and broader guideline recommendations.
No, doripenem does not cover methicillin-resistant Staphylococcus aureus (MRSA). Carbapenems, including doripenem, are generally not effective against MRSA, and alternative agents like vancomycin, daptomycin, or linezolid should be used for MRSA infections.
